MedTrace Logo

Second-Line Treatment Choice for Epilepsy

NCT00208520 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2006-09-12

No results posted yet for this study

Summary

Most patients are prescribed valproate as their first antiepileptic drug. It is unknown which is the best second-line drug when patients do not become seizure free on valproate. This has led the Dutch Epilepsy Clinics Foundation (SEIN) to start the SLICE study. Adult patients with partial and/or tonic-clonic seizures, insufficiently responding to valproate, are recruited for this study. These patients are randomized to receive one of three other drugs. Patients wil initially use this drug next to valproate. Neurologists of more than 20 general hospitals en neurologists of SEIN are participating in this study.

Conditions

  • Adults With Tonic Clonic Seizures and/or Partial Seizures

Interventions

DRUG

Carbamazepine

DRUG

Lamotrigine

DRUG

Levetiracetam

Sponsors & Collaborators

  • Dutch Epilepsy Clinics Foundation

    lead OTHER

Principal Investigators

  • Charles L Deckers, MD, PhD · Dutch Epilepsy Clinics Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Completion
2007-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00208520 on ClinicalTrials.gov